UST-IPK School Researchers Uncover Therapeutic Potential for Liver and Pulmonary Fibrosis
2026-09-16
UST-IPK School Researchers Uncover Therapeutic Potential
for Liver and Pulmonary Fibrosis
- Findings highlight the potential of the anti-fibrotic candidate ABRL8301 for therapeutic development -
- Studies led by Ph.D. students in Advanced Drug Discovery & Development at the UST-IPK School -
▲ Seungeun Lee and SoWon Heo, Ph.D. students in UST-IPK School.
(Sep. 16, 2026, Gyeonggi-do, Rep. of Korea) Institut Pasteur Korea (IPK) announced that researchers at the University of Science and Technology (UST)-IPK School have published two studies in international scientific journals.
Under the supervision of Professor Haeng Ran Seo, Representative Professor of the UST-IPK School and Head of the Advanced Biomedical Research Lab at IPK, Ph.D. students Seungeun Lee and SoWon Heo investigated the anti-fibrotic candidate ABRL8301 and elucidated its mechanisms of action in suppressing fibrosis in the liver and lungs, respectively.
The study led by Seungeun Lee as first author was published in Phytomedicine, an international scientific journal ranked in the top 1% of its field.
Hepatic fibrosis is a condition in which repeated liver injury leads to excessive accumulation of collagen and other extracellular matrix components, causing liver tissue to progressively stiffen. Lee approached hepatic fibrosis from a metabolic perspective, focusing particularly on the role of arginine. The study demonstrated that ABRL8301 modulates arginine metabolism in the liver, thereby suppressing hepatic stellate cell activation and collagen deposition. These findings suggest a potential new therapeutic strategy for hepatic fibrosis through the modulation of arginine metabolism.
In another study led by SoWon Heo as first author, the researchers elucidated the anti-fibrotic effects of ABRL8301 against progressive pulmonary fibrosis (PPF) and its underlying mechanism of action. The study showed that ABRL8301 modulates cellular responses and inflammatory signaling associated with pulmonary fibrosis while reducing the accumulation of extracellular matrix proteins, including collagen. The findings were published in the international scientific journal European Journal of Pharmacology.
The two studies are notable in that they elucidated distinct mechanisms by which a single candidate compound exerts anti-fibrotic effects in diseases affecting different organs. Together, the findings highlight the potential of ABRL8301 as a therapeutic candidate for a range of fibrotic diseases.
Meanwhile, IPK became the first private, non-profit research institute in Korea to be designated as a UST campus in 2014 and was accredited as a UST School in the second half of 2023. The UST-IPK School offers master’s, Ph.D., and integrated master’s and Ph.D. programs in Advanced Drug Discovery & Development, fostering the next generation of global experts in infectious disease research.
Sung Key Jang, CEO of IPK, said, “Building on IPK’s research capabilities and expertise, we will continue to foster the next generation of researchers who will lead the fields of infectious diseases and drug discovery.”